{"id":1224,"date":"2002-09-01T12:06:00","date_gmt":"2002-09-01T10:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/wichtige-neue-daten-der-hers-ii-studie"},"modified":"2002-09-01T12:06:00","modified_gmt":"2002-09-01T10:06:00","slug":"wichtige-neue-daten-der-hers-ii-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/wichtige-neue-daten-der-hers-ii-studie","title":{"rendered":"Wichtige neue Daten der HERS-II-Studie"},"content":{"rendered":"<p>Wir haben 1998 und 1999 im ARZNEIMITTELBRIEF bereits die Heart and Estrogen\/Progestin Replacement Study (HERS) besprochen, eine doppeltblinde, randomisierte Studie zur Sekund\u00e4rpr\u00e4vention der Koronaren Herzkrankheit (KHK) mit \u00d6strogenen\/(Gestagenen) bei postmenopausalen Frauen (1, 2). In unserem Leitartikel vom M\u00e4rz 2001 (3) wurde nochmals darauf eingegangen. Die Auswertung von HERS nach 4,1 Jahren Laufzeit hatte vermehrt tiefe [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wir haben 1998 und 1999 im ARZNEIMITTELBRIEF bereits die Heart and Estrogen\/Progestin Replacement Study (HERS) besprochen, eine doppeltblinde, randomisierte Studie zur Sekund\u00e4rpr\u00e4vention der Koronaren Herzkrankheit (KHK) mit \u00d6strogenen\/(Gestagenen) bei postmenopausalen Frauen (1, 2). In unserem Leitartikel vom M\u00e4rz 2001 (3) wurde nochmals darauf eingegangen. Die Auswertung von HERS nach 4,1 Jahren Laufzeit hatte vermehrt tiefe [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[61,59,57,3026,71,498,69,65,62,66,54,51,55],"class_list":["post-1224","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-beinvenenthrombose","tag-estrogene","tag-estrogene-gestagene","tag-hers-ii-studie","tag-herzinfarkt","tag-koronare-herzkrankheit","tag-lungenembolie","tag-myokardinfarkt","tag-oestrogene","tag-oestrogene-gestagene","tag-thromboembolie","tag-thrombose","tag-venenthrombose"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1224","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1224"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1224\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1224"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1224"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}